Roles of prostaglandin E2 in cardiovascular diseases focus on the potential use of a novel selective EP4 receptor agonist

International Heart Journal

Volumn 52, Issue 5, 2011, Pages 266-269

  Suzuki, Jun ichi ^a   Ogawa, Masahito ^a   Watanabe, Ryo ^b   Takayama, Kiyoshi ^a   Hirata, Yasunobu ^a   Nagai, Ryozo ^a   Isobe, Mitsuaki ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Chemokine; Heart; Macrophage; Prostaglandin; Receptors

Indexed keywords

16,16 DIMETHYLPROSTAGLANDIN E2; 17 PHENYL TRINOR PROSTAGLANDIN E2; 19 HYDROXY PROSTAGLANDIN E2; AHI 3205; CICAPROST; EVATANEPAG; MISOPROSTOL; ONO AE 248; ONO AE1 239; ONO AE1 259; ONO DI 004; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E RECEPTOR 4 AGONIST; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; SC 46275; SULPROSTONE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; BRAIN INFARCTION; BRAIN ISCHEMIA; CARDIAC GRAFT REJECTION; CARDIOVASCULAR DISEASE; CONTACT ALLERGY; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG STRUCTURE; FRACTURE; GRAFT SURVIVAL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART TRANSPLANTATION; HUMAN; INFLAMMATION; MYOCARDITIS; MYOELECTRICITY; NERVE SPROUTING; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TRANSPLANTATION TOLERANCE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CARDIOVASCULAR DISEASES; CHEMOKINES; CYTOKINES; DINOPROSTONE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; INFLAMMATION MEDIATORS; RECEPTORS, PROSTAGLANDIN E; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80054744222     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.52.266     Document Type: Review

References (57)

1. Sakata D, Yao C, Narumiya S. Emerging roles of prostanoids in T cell-mediated immunity. IUBMB Life 2010; 62: 591-6. (Review)
2. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999; 79: 1193-226. (Review)
3. Cha YI, Solnica-Krezel L, DuBois RN. Fishing for prostanoids: deciphering the developmental functions of cyclooxygenase-de-rived prostaglandins. Dev Biol 2006; 289: 263-72. (Review)
4. Jabbour HN, Sales KJ, Smith O P, Battersby S, Boddy SC. Prosta-glandin receptors are mediators of vascular function in endometrial pathologies. Mol Cell Endocrinol 2006; 252: 191-200. (Review)
5. Yuhki K, Kojima F, Kashiwagi H, et al. Roles of prostanoids in the pathogenesis of cardiovascular diseases: Novel insights from knockout mouse studies. Pharmacol Ther 2011; 129: 195-205. (Review)
6. Wang M, Zukas AM, Hui Y, Ricciotti E, Puré E, FitzGerald GA. Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci USA 2006; 103: 14507-12.
7. Degousee N, Fazel S, Angoulvant D, et al. Microsomal prosta-glandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction. Circulation 2008; 117: 1701-10.
8. Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 2001; 108: 15-23. (Review)
9. Furuyashiki T, Narumiya S. Stress responses: the contribution of prostaglandin E2 and its receptors. Nat Rev Endocrinol 2011; 7: 163-75. (Review)
10. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994; 46: 205-29. (Review)
11. Southall MD, Vasko MR. Prostaglandin receptor subtypes, EP3C and EP4, mediate the prostaglandin E2-induced cAMP production and sensitization of sensory neurons. J Biol Chem 2001; 276: 16083-91.
12. Takayama K, Garcia-Cardena G, Sukhova GK, Comander J, Gim-brone MA Jr, Libby P. Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 2002; 277: 44147-54.
13. Nataraj C, Thomas DW, Tilley SL, et al. Receptors for prostaglan-din E2 that regulate cellular immune responses in the mouse. J Clin Invest 2001; 108: 1229-35.
14. Morichika T, Takahashi HK, Iwagaki H, et al. Effect of prosta-glandin E2 on intercellular adhesion molecule-1 and B7 expression in mixed lymphocyte reaction. Transplantation 2003; 75: 2100-05.
15. Suzawa T, Miyaura C, Inada M, et al. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 2000; 141: 1554-9.
16. Jones RL, Giembycz MA, Woodward DF. Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol 2009; 158: 104-45. (Review)
17. Norel X. Prostanoid receptors in the human vascular wall. Scientific World Journal 2007; 7: 1359-74. (Review)
18. Mizuguchi S, Ohno T, Hattori Y, et al. Roles of prostaglandin E2-EP1 receptor signaling in regulation of gastric motor activity and emptying. Am J Physiol Gastrointest Liver Physiol 2010; 299: G1078-86.
19. Rutkai I, Feher A, Erdei N, et al. Activation of prostaglandin E2 EP1 receptor increases arteriolar tone and blood pressure in mice with type 2 diabetes. Cardiovasc Res 2009; 83: 148-54.
20. Ahmad M, Saleem S, Shah Z, Maruyama T, Narumiya S, Doré S. The PGE2 EP2 receptor and its selective activation are beneficial against ischemic stroke. Exp Transl Stroke Med 2010; 2: 12.
21. Mori A, Saito M, Sakamoto K, Narita M, Nakahara T, Ishii K. Stimulation of prostanoid IP and EP2 receptors dilates retinal arte-rioles and increases retinal and choroidal blood flow in rats. Eur J Pharmacol 2007; 570: 135-41.
22. Kajimoto M, Ichiyama T, Ueno Y, Shiraishi M, Hasegawa M, Fu-rukawa S. Enhancement of activated beta1-integrin expression by prostaglandin E2 via EP receptors in isolated human coronary arterial endothelial cells: implication for the treatment of Kawasaki disease. Infamm Res 2009; 58: 224-8.
23. Cameron KO, Lefker BA, Ke HZ, et al. Discovery of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation. Bioorg Med Chem Lett 2009; 19: 2075-8.
24. Woodward DF, Protzman CE, Krauss AH, Williams LS. Identification of 19 (R)-OH prostaglandin E2 as a selective prostanoid EP2-receptor agonist. Prostaglandins 1993; 46: 371-83.
25. Richter M, Krauss AH, Woodward DF, Lütjen-Drecoll E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest Ophthalmol Vis Sci 2003; 44: 4419-26.
26. Li J, Liang X, Wang Q, Breyer RM, McCullough L, Andreasson K. Misoprostol, an anti-ulcer agent and PGE2 receptor agonist, protects against cerebral ischemia. Neurosci Lett 2008; 438: 210-5.
27. Ikeda-Matsuo Y, Tanji H, Ota A, et al. Microsomal prostaglandin E synthase-1 contributes to ischaemic excitotoxicity through pros-taglandin E2 EP3 receptors. Br J Pharmacol 2010; 160: 847-59.
28. Honda T, Matsuoka T, Ueta M, Kabashima K, Miyachi Y, Naru-miya S. Prostaglandin E(2)-EP(3) signaling suppresses skin inflammation in murine contact hypersensitivity. J Allergy Clin Immunol 2009; 124: 809-18.
29. Aihara E, Nomura Y, Sasaki Y, Ise F, Kita K, Takeuchi K. Involvement of prostaglandin E receptor EP3 subtype in duodenal bicarbonate secretion in rats. Life Sci 2007; 80: 2446-53.
30. Konger RL, Brouxhon S, Partillo S, VanBuskirk J, Pentland A P. The EP3 receptor stimulates ceramide and diacylglycerol release and inhibits growth of primary keratinocytes. Exp Dermatol 2005; 14: 914-22.
31. Savage MA, Moummi C, Karabatsos PJ, Lanthorn TH. SC-46275: a potent and highly selective agonist at the EP3 receptor. Prostag-landins Leukot Essent Fatty Acids 1993; 49: 939-43.
32. Widomski D, Fretland DJ, Gasiecki AF, Collins PW. The prosta-glandin analogs, misoprostol and SC-46275, potently inhibit cy-tokine release from activated human monocytes. Immunopharma-col Immunotoxicol 1997; 19: 165-74.
33. Kotani M, Tanaka I, Ogawa Y, et al. Multiple signal transduction pathways through two prostaglandin E receptor EP3 subtype iso-forms expressed in human uterus. J Clin Endocrinol Metab 2000; 85: 4315-22.
34. Foudi N, Kotelevets L, Louedec L, et al. Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: role of the EP4 receptor subtype. Br J Pharmacol 2008; 154: 1631-9.
35. Sakamoto A, Matsumura J, Mii S, Gotoh Y, Ogawa R. A prosta-glandin E2 receptor subtype EP4 agonist attenuates cardiovascular depression in endotoxin shock by inhibiting inflammatory cy-tokines and nitric oxide production. Shock 2004; 22: 76-81.
36. Hristovska AM, Rasmussen LE, Hansen PB, et al. Prostaglandin E2 induces vascular relaxation by E-prostanoid 4 receptor-mediated activation of endothelial nitric oxide synthase. Hypertension 2007; 50: 525-30.
37. Pfeffer MA, Braunwald E. Ventricular remodeling after myocar-dial infarction. Experimental observations and clinical implications. Circulation 1990; 81: 1161-72. (Review)
38. Cohen MV, Baines CP, Downey JM. Ischemic preconditioning: from adenosine receptor to KATP channel. Annu Rev Physiol 2000; 62: 79-109. (Review)
39. Bolli R. The late phase of preconditioning. Circ Res 2000; 87: 972-83. (Review)
40. Martin M, Meyer-Kirchrath J, Kaber G, et al. Cardiospecific over-expression of the prostaglandin EP3 receptor attenuates ischemia-induced myocardial injury. Circulation 2005; 112: 400-6.
41. Hohlfeld T, Meyer-Kirchrath J, Vogel YC, Schrör K. Reduction of infarct size by selective stimulation of prostaglandin EP(3) receptors in the reperfused ischemic pig heart. J Mol Cell Cardiol 2000; 32: 285-96.
42. Hishikari K, Suzuki J, Ogawa M, et al. Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury. Cardiovasc Res 2009; 81: 123-32.
43. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh offcial adult heart transplant report--2010. J Heart Lung Transplant 2010; 29: 1089-103.
44. Stone CD, Rosengard BR, Boorstein SM, Robbins RC, Hennein HA, Clark RE. Prostaglandin E2 inhibits in vitro and in vivo lymphocyte responses in allogeneic transplantation. Ann Thorac Surg 1990; 49: 927-30.
45. Kamei T, Callery MP, Flye MW. Intragraft delivery of 16, 16-dimethyl PGE2 induces donor-specifc tolerance in rat cardiac allograft recipients. Transplantation 1991; 51: 242-6.
46. Wanders A, Tufveson G, Gerdin B. Effects of prostaglandin E2 (PGE2) and drugs affecting PGE2 degradation on acute rejection of rat cardiac allografts. Scand J Thorac Cardiovasc Surg 1992; 26: 33-7.
47. Nomi T, Sho M, Akahori T, Kanehiro H, Nakajima Y. Protective effect of prostaglandin E2 receptors EP2 and EP4 in alloimmune response in vivo. Transplant Proc 2006; 38: 3209-10.
48. Ogawa M, Suzuki J, Kosuge H, Takayama K, Nagai R, Isobe M. The mechanism of anti-inflammatory effects of prostaglandin E2 receptor 4 activation in murine cardiac transplantation. Transplantation 2009; 87: 1645-53.
49. Blauwet LA, Cooper LT. Myocarditis. Prog Cardiovasc Dis 2010; 52: 274-88. (Review)
50. Cooper LT Jr. Myocarditis. N Engl J Med 2009; 360: 1526-38. (Review)
51. Takahashi T, Zhu SJ, Sumino H, et al. Inhibition of cyclooxygen-ase-2 enhances myocardial damage in a mouse model of viral myocarditis. Life Sci 2005; 78: 195-204.
52. Ishiyama S, Hiroe M, Nishikawa T, et al. Nitric oxide contributes to the progression of myocardial damage in experimental autoimmune myocarditis in rats. Circulation 1997; 95: 489-96.
53. Inomata T, Hanawa H, Miyanishi T, et al. Localization of porcine cardiac myosin epitopes that induce experimental autoimmune myocarditis. Circ Res 1995; 76: 726-33.
54. Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 2001; 108: 15-23. (Review)
55. Harris SG, Padilla J, Koumas L, Ray D, Phipps R P. Prostaglandins as modulators of immunity. Trends Immunol 2002; 23: 144-50. (Review)
56. Aronoff DM, Canetti C, Peters-Golden M. A prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. J Immunol 2004; 173: 559-65.
57. Ngoc PB, Suzuki J, Ogawa M, et al. The anti-inflammatory mechanism of prostaglandin E2 receptor 4 activation in rat experimental autoimmune myocarditis. J Cardiovasc Pharmacol 2011; 57: 365-72.